Espr stock news
You're looking for news about Esperion Therapeutics, Inc. (ESPR) stock! Here are some recent updates:
Recent News:
- Esperion Therapeutics Reports Q4 2022 Financial Results: On February 23, 2023, Esperion Therapeutics announced its financial results for the fourth quarter and full year 2022. The company reported a net loss of $43.6 million for the quarter and a net loss of $173.4 million for the full year. (Source: Business Wire)
- Esperion Therapeutics Presents Data on Bempedoic Acid at ACC.23/WCC: On March 4, 2023, Esperion Therapeutics presented new data on bempedoic acid, its lead product candidate, at the American College of Cardiology's (ACC) 72nd Annual Scientific Session & Expo. The data showed that bempedoic acid reduced LDL cholesterol by 18.4% compared to placebo in patients with heterozygous familial hypercholesterolemia (HeFH). (Source: Business Wire)
- Esperion Therapeutics Announces FDA Approval of Bempedoic Acid: On November 18, 2022, Esperion Therapeutics announced that the U.S. Food and Drug Administration (FDA) had approved bempedoic acid, a first-in-class, oral, once-daily, ATP citrate lyase (ACL) inhibitor, for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD). (Source: Business Wire)
Stock Performance:
As of March 10, 2023, Esperion Therapeutics' stock (ESPR) is trading at around $23.50 per share, with a market capitalization of approximately $1.3 billion. The stock has been relatively stable over the past year, with a 52-week range of $14.50 to $28.50.
Analyst Estimates:
According to Refinitiv, the average analyst estimate for Esperion Therapeutics' stock price is around $25.50 per share, with a high estimate of $35.00 and a low estimate of $18.00.
Risk Factors:
As with any biotech stock, there are risks associated with investing in Esperion Therapeutics. Some of the key risks include:
- Clinical trial results: Esperion Therapeutics' clinical trials may not produce the desired results, which could impact the company's ability to commercialize its products.
- Competition: The company faces competition from other biotech companies and pharmaceutical companies that are developing similar products.
- Regulatory approval: Esperion Therapeutics may not receive regulatory approval for its products, which could impact the company's ability to commercialize them.
- Financial performance: The company's financial performance may not meet analyst estimates, which could impact the stock price.
I hope this information helps!